创伤性脑损伤后神经递质变化:新治疗策略的更新
本文综述创伤性脑损伤(TBI)后神经递质传递的病理改变,结合临床前与临床研究经验,指出尽管动物模型治疗成功但临床转化失败,强调需重新定义TBI分类并深入理解与恢复或慢性症状相关的机制,为未来临床试验提供方向。
要点
- TBI后认知障碍与精神疾病(尤其焦虑抑郁)高发,提示神经传递持久改变。
- 动物模型治疗成功未能转化为人类临床疗效,需反思研究策略。
- 未来需聚焦与恢复 versus 慢性症状发展相关的病理生理机制。
核心结论
- TBI后神经递质传递改变可能与认知及精神症状(如焦虑抑郁)持续存在相关,但既往基于动物模型的临床试验未能转化成功。
- 国际努力正重新定义TBI分类与特征,未来试验需基于过去二十年研究经验优化假设。
研究设计与样本
- 综述类文章,聚焦TBI后神经传递病理,汇总临床前与临床研究证据。
主要发现
- TBI诊断个体数逐年增加且无有效治疗干预。
- 大量患者伤后出现认知障碍和精神疾病,尤其焦虑和抑郁。
- 临床试验曾聚焦蛋白聚集、炎症、代谢紊乱、细胞生成、生理及神经递质信号改变等机制,但动物模型成功未能在人类重现。
临床怎么用
- 临床应关注TBI后焦虑抑郁等精神症状的评估与干预。
- 未来治疗策略需基于重新定义的TBI分类和与恢复或慢性症状相关的机制。
局限性
- 原文未报告具体研究样本量、效应值或统计阈值。
- 综述未提供定量汇总数据或荟萃分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traumatic brain injury (TBI) is a pervasive problem in the United States and worldwide, as the number of diagnosed individuals is increasing yearly and there are no efficacious therapeutic interventions. A large number of patients suffer with cognitive disabilities and psychiatric conditions after TBI, especially anxiety and depression. The constellation of post-injury cognitive and behavioral symptoms suggest permanent effects of injury on neurotransmission. Guided in part by preclinical studies, clinical trials have focused on high-yield pathophysiologic mechanisms, including protein aggregation, inflammation, metabolic disruption, cell generation, physiology, and alterations in neurotransmitter signaling. Despite successful treatment of experimental TBI in animal models, clinical studies based on these findings have failed to translate to humans. The current international effort to reshape TBI research is focusing on redefining the taxonomy and characterization of TBI. In addition, as the next round of clinical trials is pending, there is a pressing need to consider what the field has learned over the past two decades of research, and how we can best capitalize on this knowledge to inform the hypotheses for future innovations. Thus, it is critically important to extend our understanding of the pathophysiology of TBI, particularly to mechanisms that are associated with recovery versus development of chronic symptoms. In this review, we focus on the pathology of neurotransmission after TBI, reflecting on what has been learned from both the preclinical and clinical studies, and we discuss new directions and opportunities for future work.
引用
- McGuire JL, Ngwenya LB, McCullumsmith RE, et al. Neurotransmitter changes after traumatic brain injury: an update for new treatment strategies. Mol Psychiatry. 2018. PMID: 30214042. doi:10.1038/s41380-018-0239-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。